ArticleOncoimmunology
Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Radiogenomic Profiling for Survival Analysis in Gastric Cancer: Integrating CT Imaging, Gene Expression, and Clinical Data.Molecular imaging and biology · 2025Article
- An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia.Blood advances · 2022Article
- Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma.Frontiers in oncology · 2022Article
- Diverse 'just-right' levels of chromosomal instability and their clinical implications in neoadjuvant treated gastric cancer.British journal of cancer · 2021Article
- Identification of gastric cancer subtypes based on pathway clustering.NPJ precision oncology · 2021Article
- DNA-protein biomarkers for immunotherapy in the era of precision oncology.Journal of pathology and translational medicine · 2021Review
- Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial.Oncoimmunology · 2020Article
- Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis.Annals of translational medicine · 2020Article
- Review
- Differential prognostic impact of CD8British journal of cancer · 2020Article
- Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy.Frontiers in cell and developmental biology · 2020Article
- Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors.International journal of molecular sciences · 2019Review
- Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.Frontiers of medicine · 2019Review
- New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019Article
- Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies.Translational gastroenterology and hepatology · 2019Review
- Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.Frontiers in immunology · 2019Review
- Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018Article
- Computational measurement of tumor immune microenvironment in gastric adenocarcinomas.Scientific reports · 2018Article
- The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.International journal of molecular sciences · 2018Article
- TIMP2 is a Poor Prognostic Factor and Predicts Metastatic Biological Behavior in Gastric Cancer.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor infiltrating lymphocytes (TIL) in Epstein-Barr virus (EBV)-associated/microsatellite-unstable (MSI) gastric carcinomas (GC) constitute immune-active principal cellular components of tumor microenvironment and contribute to better prognosis. With the remarkable success of cancer immunotherapies, there is an urgent need for a comprehensive understanding of tumor-immune interactions in patients with GC in the context of host immune response. To identify GC subtype-specific immune response gene set, we tested differentially expressed genes for MSI and EBV+ GC subtypes in randomly selected test set (n = 278) in merged ACRG-SMC microarray and TCGA RNA sequencing data set. We identified Host ImmunE Response index (HIERÏ) consisting of 29 immune genes classifying GC patients into robust 3 groups with prognostic significance. Immune-high cluster 1 was enriched with PD-L1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.